User Login  
Username
Password

   
smr committee

 
 

Chair: Prof Simon E. Ward MA PhD
Simon Ward is the Sêr Cymru Professor in Translational Drug Discovery and Director of the Medicines Discovery Institute at Cardiff University. He has wide ranging experience of drug discovery in both major pharmaceutical companies, biotech & academia (GlaxoSmithKline, BioCrea, Knoll Pharmaceuticals, Vernalis, Chiroscience, University of Sussex, Cardiff University) and specialist experience of discovering and developing drugs for patients with neurological and psychiatric illness and against cancers. He has led multidisciplinary project teams & medicinal chemistry groups from early stages through to clinical studies, bringing multiple molecules into clinical development for a wide range of diseases.

e-mail: WardS10@cardiff.ac.uk

Communications Officer: Dr Farnaz Fallah-Arani
Farnaz is currently a senior group leader in the Therapeutic area of immunology at UCB Celltech in Slough and has experience in pre-clinical research and drug discovery of biologics and small molecules. Farnaz is an Immunologist by training and has a strong interest in the biology of autoimmune disease, immunemodulation and transplantation.

e-mail: farnaz.fallah-arani@ucb.com

Development Officer: Dr Gregor Macdonald B.Sc., Ph.D.
Gregor is Senior Director of Scientific Licensing (Neuroscience), within Janssen Business Development, the Pharmaceutical Companies of J&J. In this role, he leads the global identification and evaluation of all clinical stage therapeutic opportunities in Neuroscience, particularly focussed on Alzheimer's disease, Mood disorders and Schizophrenia. Prior to this position, Gregor was Head of Neuroscience Medicinal Chemistry at Janssen, where he led discovery teams in Belgium and Spain towards the identification of clinical drug candidates in the fields of Alzheimer's disease, schizophrenia and order psychiatric and neurological disorders. In addition, Gregor was also extensively involved in identifying external drug discovery opportunities and prosecuting research collaborations with a variety of academic, biotech and pharma partners. Previously, he has worked within the Medicinal Chemistry depts. of GlaxoSmithKline and SmithKline Beecham, also in the CNS area, identifying several late clinical stage drug candidates. Gregor is also a co-author and co-inventor on over 110 scientific publications and patents and has been an invited speaker and panellist at several national and international conferences.

e-mail: gmacdon1@its.jnj.com

Fundraising Officer: Dr James Ritchie PhD
James is currently a Drug Development Scientist at Cancer Research UK's Drug Development Office. He has been working in the field of oncology drug discovery and development since 2001, having worked previously at TopoTarget A/S (formerly Prolifix Ltd) for 8 years. James's interests are in the translational and clinical development of new anti-cancer agents covering everything from small molecules to immune therapies.

e-mail: james.ritchie@cancer.org.uk

Honorary Secretary: Dr Peter Weber
Peter is Director of Autoimmune Research at Immunocore Ltd. (Abingdon, Oxfordshire), a world leading T Cell Receptor (TCR) biotechnology company, where he heads the Autoimmune department and is responsible for strategic leadership. Previously Peter worked for nearly 18 years at Vertex Pharmaceuticals (Europe) Ltd, where he contributed significantly to the foundation and growth of its UK site. Peter has a strong background in drug discovery, has led several drug discovery LO programs and has extensive experience in leading biology groups and multidisciplinary project teams. His main interests are in the areas of inflammation and oncology.

e-mail: peter.weber@immunocore.com

Honorary Treasurer: Dr Richard Davenport MSc, PhD, Post
Richard is currently a Senior Programme Leader at C4X Discovery working on Inflammation and CNS programmes. Richard has over 20 years' experience of drug discovery research and has previously held senior medicinal chemistry positions at Takeda Pharmaceuticals, UCB and Celltech working in the therapeutic areas of Inflammation, CNS and Metabolism.

e-mail: richard.davenport@c4xdiscovery.com

SMR Secretariat: Mr Stuart Hex
e-mail: shex_327@hotmail.com

SMR Secretariat: Ms Josephine McEnaney
e-mail: secretariat@smr.org.uk

SMR Secretariat: Mr Chris Barron
e-mail: chris@ceeb.co.uk

Dr Mohammad Alavijeh PhD MSc BSc
Mo is director of research at Pharmidex. His background is in drug metabolism and pharmacokinetics with particular interest in neuropharmacokinetics. He has experience in drug discovery and early phase development in a number of therapeutic areas. He has previously held positions with Vernalis, Aventis and Rhone-Poulenc Rorer.

e-mail: mo.alavijeh@pharmidex.com

Dr Darcey Black
Darcey Black s Founder/Director of TherapeutAix (www.therapeutaix.com), of recently established life-sciences consultancy, focused on providing strategic input and project management in drug discovery and early clinical development to life sciences start-ups, biotech and pharma. He has over 30 years’ experience in pre- and early clinical drug discovery working in all aspects from target ID and validation, LO and translational studies in early clinical development, in different therapeutic areas including CV, inflammation and neuroscience. Previously, he was Head External Innovation in the Innovative Medicines Unit at Grünenthal Innovation IMU, Aachen, Germany. He joined Grünenthal as Head of Translational Research in 2011. Prior to joining Grünenthal, he worked for Merck (formerly Organon/Schering-Plough) in the UK in senior project and line management roles, and for Pfizer and Glaxo (now GSK) in the UK and Switzerland.

e-mail: darcey.black@grunenthal.com

Dr Katherine Brown
Kate is a lecturer in the Department of Biological Sciences at Imperial College London. Her laboratory is part of the Centre for Molecular Microbiology and Infection located on the South Kensington campus. Her research principally involves structure-function studies of proteins from microbial pathogens with applications in vaccine and antimicrobial development.

e-mail: kb518@cam.ac.uk

Mrs Pamela Brown
Pam has over 30 years experience in anti-infective drug discovery, initially gained at GlaxoSmithKline and legacy companies, leading medicinal chemistry teams in hit to lead and lead optimisation phases of drug discovery. Pam led the chemistry at Cantab Anti-infectives Ltd which was recently bought by Spero Therapeutics. Pam Brown Consulting was formed in 2017, offering independent advice in antibacterial drug discovery and medicinal chemistry to SMEs and biotechs. Pam has over 35 publications in patents and peer-reviewed journals on the design and synthesis of antibacterial agents in a variety of antibacterial classes. She holds a degree in Chemistry and is a Fellow of the Royal Society of Chemistry.

e-mail: pamela@pambrownconsulting.com

Dr Sam Butterworth
Sam is a Senior Lecturer in Medicinal Chemistry at the University of Manchester, where his group work on applying synthetic and biological chemistry to address questions of relevance to human health. Prior to this he worked at the University of Birmingham from 2013 and at AstraZeneca from 2005-2013. His work at AstraZeneca led to the development of a targeted anti-cancer agent AZD9291, that was approved by the FDA in November 2015 and is now used internationally under the name osimertinib/Tagrisso. As of 2018 this drug has been used to treat >30,000 patients worldwide, and along with his colleagues Sam has been recognised for this work through the 2017 RSC Malcolm Campbell Award and the 2018 ACS Heroes of Chemistry award.

e-mail: sam.butterworth@manchester.ac.uk

Dr Mike Hann
Mike has over 35 years experience of Pharma drug discovery activities with Roussel, Wyeth, GD Searle and Glaxo/GlaxoWellcome/GSK, initially as a medicinal chemist, then as a computational chemist and more recently in managing teams in structural biology, biophysics and bioMS and other sciences at the interface of chemistry and biology. He has contributed to the development of concepts in computational chemistry, fragments, attrition reduction and compound disposition in cells and maintains a keen interest in new methodologies but with a firm grip on the realities of the eternal challenge that drug discovery presents.

e-mail: mmh1203@gsk.com

Dr Phil Jeffrey BSc, MSc, PhD
Phil is Senior Vice President of Preclinical Development at Bicycle Therapeutics and has over 35 years in experience of in the pharmaceutical industry. He has a successful track record in drug discovery from early lead optimisation through to clinical proof of mechanism and proof of concept across a wide variety of therapeutic areas and drug modalities. Phil previously held positions at Pfizer, GlaxoSmithKline, SmithKline Beecham and The Upjohn Company and is an Honorary Professor at the William Harvey Research Institute, Queen Mary University of London.

e-mail: phil.jeffrey@bicycletx.com

Dr Matthew Konneh
Matthew is founder and Lead Consultant of Konnsult Lifesciences Ltd, a UK based consultancy providing strategic and business development services to preclinical pharmacology and early clinical development CROs, and enables accelerated access to niche service providers for the global pharma-biotech industry. Matthew is based in London and has worked in in pre-clinical pharmacology (Novartis), clinical research ( Parexel, Biotrial) and strategic consultancy (Accenture) in the pharma industry for the past 20 years. He holds a PhD in Pharmacology and an MBA.

e-mail: matthew.konneh@gmail.com

Dr John Overington
John is currently CIO at the Medicines Discovery Catapult. He has over 30 years experience of drug discovery informatics, across academic, biotech and large pharma sectors. He has deep experience of the application of informatics methods to problems in drug discovery, ranging from target selection through to real world evidence analytics of drug patient benefits. His current professional interests focus on big data, machine learning and artificial intelligence.

e-mail: jpo@md.catapult.org.uk

Dr Rod Porter
Rod is an independent medicinal chemistry consultant working with a range of clients. Previously Rod was a medicinal chemistry group and matrix programme leader, (GlaxoSmithKline, G. D. Searle) for over 25 years, involved in projects from target id to candidate selection and working in numerous therapeutic areas with particularly emphasis on the CNS. Amongst others, areas of interests include understanding effective drug distribution and protein-protein interactions.

e-mail: rod.porter@rodporterconsultancy.com

Dr David C Pryde
David has been in the drug discovery industry for 20 years, working as a medicinal chemist in both a large pharma company and a small biotech. He has extensive experience in leading drug discovery projects from hit seeking through to clinical development candidates across a variety of therapeutic areas in both small molecule and synthetic biologic programmes.

e-mail: david@curadev.co.uk

Dr Mihiro Sunose
e-mail: M.Sunose@sygnaturediscovery.com

Dr Martin Swarbrick
e-mail: mswarbrick@cancertechnology.com

Dr Andy Sykes
Andy is currently a Senior Clinical Pharmacologist for AstraZeneca with over 20 years' experience in DMPK drug discovery and development in CNS, oncology and inflammation having held previous positions at Takeda and UCB.

e-mail: andy.sykes@astrazeneca.com

Dr Pamela Williams
Dr. Pamela Williams is an Associate Director in the Molecular Sciences group at Astex Pharmaceuticals. Pamela is a structural biologist working in X-ray crystallography and cryoEM, and has worked on many fragment screening campaigns in her 15+ years in industry.

e-mail: pamela.williams@astx.com

Dr Stephen Wren
Dr Stephen Wren is highly experienced in medicinal chemistry and has worked on a diverse set of biological targets over many disease areas in several organisations (Xenova, Argenta Discovery and Summit plc). He has an extensive track record in project and team management, intellectual property, drug discovery in many therapeutic areas. An example highlight of Stephen's work was helping to lead the chemistry effort directed towards the identification of SMTC1100 (Summit's Duchenne Muscular Dystrophy drug, currently undergoing clinical evaluation).

e-mail: stephenpaulwren@gmail.com

 

   Home / Meetings / Membership / Student Bursaries / Administration /
   History of the SMR / SMR Award / Archive Material / Links / Privacy Policy / Contact Us
terms of use | smr 2019